392 related articles for article (PubMed ID: 31646981)
1. Nal-IRI with 5-fluorouracil (5-FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary tract cancer - the NIFE trial (AIO-YMO HEP-0315) an open label, non-comparative, randomized, multicenter phase II study.
Perkhofer L; Berger AW; Beutel AK; Gallmeier E; Angermeier S; Fischer von Weikersthal L; Goetze TO; Muche R; Seufferlein T; Ettrich TJ
BMC Cancer; 2019 Oct; 19(1):990. PubMed ID: 31646981
[TBL] [Abstract][Full Text] [Related]
2. Nanoliposomal Irinotecan With Fluorouracil and Leucovorin or Gemcitabine Plus Cisplatin in Advanced Cholangiocarcinoma: A Phase II Study of the AIO Hepatobiliary-YMO Cancer Groups (NIFE-AIO-YMO HEP-0315).
Ettrich TJ; Modest DP; Sinn M; Striefler JK; Opitz B; Goetze T; Gallmeier E; Angermeier S; Fischer von Weikersthal L; Jacobasch L; Waldschmidt D; Niedermeier M; Sohm M; Berger AW; Manzini G; Fehrenbach U; Auer TA; Hosse C; Vogele D; Sookthai D; Schaaf M; Muche R; Hinke A; Seufferlein T; Perkhofer L
J Clin Oncol; 2024 Jun; ():JCO2301566. PubMed ID: 38843469
[TBL] [Abstract][Full Text] [Related]
3. Treatment With Liposomal Irinotecan Plus Fluorouracil and Leucovorin for Patients With Previously Treated Metastatic Biliary Tract Cancer: The Phase 2b NIFTY Randomized Clinical Trial.
Hyung J; Kim I; Kim KP; Ryoo BY; Jeong JH; Kang MJ; Cheon J; Kang BW; Ryu H; Lee JS; Kim KW; Abou-Alfa GK; Yoo C
JAMA Oncol; 2023 May; 9(5):692-699. PubMed ID: 36951834
[TBL] [Abstract][Full Text] [Related]
4. Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial.
Lamarca A; Palmer DH; Wasan HS; Ross PJ; Ma YT; Arora A; Falk S; Gillmore R; Wadsley J; Patel K; Anthoney A; Maraveyas A; Iveson T; Waters JS; Hobbs C; Barber S; Ryder WD; Ramage J; Davies LM; Bridgewater JA; Valle JW;
Lancet Oncol; 2021 May; 22(5):690-701. PubMed ID: 33798493
[TBL] [Abstract][Full Text] [Related]
5. nal-IRI+5-FU/LV versus 5-FU/LV in post-gemcitabine metastatic pancreatic cancer: Randomized phase 2 trial in Japanese patients.
Ueno M; Nakamori S; Sugimori K; Kanai M; Ikeda M; Ozaka M; Furukawa M; Okusaka T; Kawabe K; Furuse J; Komatsu Y; Ishii H; Sato A; Shimizu S; Chugh P; Tang R; Ioka T
Cancer Med; 2020 Dec; 9(24):9396-9408. PubMed ID: 33099898
[TBL] [Abstract][Full Text] [Related]
6. Study protocol of an open-label, single arm phase II trial investigating the efficacy and safety of Trifluridine/Tipiracil combined with irinotecan as a second line therapy in patients with cholangiocarcinoma (TRITICC).
Kehmann L; Berres ML; Gonzalez-Carmona M; Modest DP; Mohr R; Wree A; Venerito M; Strassburg C; Keitel V; Trautwein C; Luedde T; Roderburg C
BMC Cancer; 2023 May; 23(1):470. PubMed ID: 37217885
[TBL] [Abstract][Full Text] [Related]
7. Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial.
Valle JW; Wasan H; Lopes A; Backen AC; Palmer DH; Morris K; Duggan M; Cunningham D; Anthoney DA; Corrie P; Madhusudan S; Maraveyas A; Ross PJ; Waters JS; Steward WP; Rees C; Beare S; Dive C; Bridgewater JA
Lancet Oncol; 2015 Aug; 16(8):967-78. PubMed ID: 26179201
[TBL] [Abstract][Full Text] [Related]
8. Modified FOLFIRINOX versus CisGem first-line chemotherapy for locally advanced non resectable or metastatic biliary tract cancer (AMEBICA)-PRODIGE 38: Study protocol for a randomized controlled multicenter phase II/III study.
Phelip JM; Edeline J; Blanc JF; Barbier E; Michel P; Bourgeois V; Neuzillet C; Malka D; Manfredi S; Desrame J;
Dig Liver Dis; 2019 Feb; 51(2):318-320. PubMed ID: 30581069
[TBL] [Abstract][Full Text] [Related]
9. Sintilimab plus nab-paclitaxel as second-line treatment for advanced biliary tract cancer: study protocol for an investigator-initiated phase 2 trial (NapaSinti trial).
Zhou N; Li X; Yang Y; Tan S; Zhang S; Huang Q; Gou H
BMC Cancer; 2023 Aug; 23(1):729. PubMed ID: 37550655
[TBL] [Abstract][Full Text] [Related]
10. NET-02 trial protocol: a multicentre, randomised, parallel group, open-label, phase II, single-stage selection trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients with progressive poorly differentiated extrapulmonary neuroendocrine carcinoma (NEC).
Craig Z; Swain J; Batman E; Wadsley J; Reed N; Faluyi O; Cave J; Sharma R; Chau I; Wall L; Lamarca A; Hubner R; Mansoor W; Sarker D; Meyer T; Cairns DA; Howard H; Valle JW; McNamara MG
BMJ Open; 2020 Feb; 10(2):e034527. PubMed ID: 32029495
[TBL] [Abstract][Full Text] [Related]
11. A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY Tract Cancers (BTC) at high risk for recurrence: PURITY study.
Niger M; Nichetti F; Fornaro L; Pircher C; Morano F; Palermo F; Rimassa L; Pressiani T; Berardi R; Gardini AC; Sperti E; Salvatore L; Melisi D; Bergamo F; Siena S; Mosconi S; Longarini R; Arcangeli G; Corallo S; Delliponti L; Tamberi S; Fea E; Brandi G; Rapposelli IG; Salati M; Baili P; Miceli R; Ljevar S; Cavallo I; Sottotetti E; Martinetti A; Busset MDD; Sposito C; Di Bartolomeo M; Pietrantonio F; de Braud F; Mazzaferro V
BMC Cancer; 2024 Apr; 24(1):436. PubMed ID: 38589856
[TBL] [Abstract][Full Text] [Related]
12. Is There Room for Liposomal Irinotecan in Biliary Tract Cancer? A Meta-analysis of Randomised Trials.
Merz V; Messina C; Zecchetto C; Quinzii A; Frisinghelli M; Trentin C; Salati M; Caffo O; Melisi D
Clin Oncol (R Coll Radiol); 2024 Feb; 36(2):87-97. PubMed ID: 38129199
[TBL] [Abstract][Full Text] [Related]
13. Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial.
Morizane C; Okusaka T; Mizusawa J; Katayama H; Ueno M; Ikeda M; Ozaka M; Okano N; Sugimori K; Fukutomi A; Hara H; Mizuno N; Yanagimoto H; Wada K; Tobimatsu K; Yane K; Nakamori S; Yamaguchi H; Asagi A; Yukisawa S; Kojima Y; Kawabe K; Kawamoto Y; Sugimoto R; Iwai T; Nakamura K; Miyakawa H; Yamashita T; Hosokawa A; Ioka T; Kato N; Shioji K; Shimizu K; Nakagohri T; Kamata K; Ishii H; Furuse J;
Ann Oncol; 2019 Dec; 30(12):1950-1958. PubMed ID: 31566666
[TBL] [Abstract][Full Text] [Related]
14. Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2 trial): study protocol for a nationwide multicenter randomized controlled trial.
Janssen QP; van Dam JL; Bonsing BA; Bos H; Bosscha KP; Coene PPLO; van Eijck CHJ; de Hingh IHJT; Karsten TM; van der Kolk MB; Patijn GA; Liem MSL; van Santvoort HC; Loosveld OJL; de Vos-Geelen J; Zonderhuis BM; Homs MYV; van Tienhoven G; Besselink MG; Wilmink JW; Groot Koerkamp B;
BMC Cancer; 2021 Mar; 21(1):300. PubMed ID: 33757440
[TBL] [Abstract][Full Text] [Related]
15. Palliative first-line therapy with weekly high-dose 5-fluorouracil and sodium folinic acid as a 24-hour infusion (AIO regimen) combined with weekly irinotecan in patients with metastatic adenocarcinoma of the stomach or esophagogastric junction followed by secondary metastatic resection after downsizing.
Koucky K; Wein A; Konturek PC; Albrecht H; Reulbach U; Männlein G; Wolff K; Ostermeier N; Busse D; Golcher H; Schildberg C; Janka R; Hohenberger W; Hahn EG; Siebler J; Neurath MF; Boxberger F
Med Sci Monit; 2011 May; 17(5):CR248-58. PubMed ID: 21525806
[TBL] [Abstract][Full Text] [Related]
16. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trial.
Burris HA; Okusaka T; Vogel A; Lee MA; Takahashi H; Breder V; Blanc JF; Li J; Bachini M; Żotkiewicz M; Abraham J; Patel N; Wang J; Ali M; Rokutanda N; Cohen G; Oh DY
Lancet Oncol; 2024 May; 25(5):626-635. PubMed ID: 38697156
[TBL] [Abstract][Full Text] [Related]
17. The GIANT trial (ECOG-ACRIN EA2186) methods paper: A randomized phase II study of gemcitabine and nab-paclitaxel compared with 5-fluorouracil, leucovorin, and liposomal irinotecan in older patients with treatment-naïve metastatic pancreatic cancer - defining a new treatment option for older vulnerable patients.
Dotan E; Catalano P; Lenchik L; Boutin R; Yao X; Marques HS; Ioffe D; Zhen DB; Li D; Wagner LI; Simon MA; Wong TZ; O'Dwyer PJ
J Geriatr Oncol; 2023 Apr; 14(3):101474. PubMed ID: 36963200
[TBL] [Abstract][Full Text] [Related]
18. Durvalumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Biliary Tract Cancer: a Real-World Retrospective, Multicenter Study.
Rimini M; Masi G; Lonardi S; Nichetti F; Pressiani T; Lavacchi D; Jessica L; Giordano G; Scartozzi M; Tamburini E; Pastorino A; Rapposelli IG; Daniele B; Martinelli E; Garajova I; Aprile G; Schirripa M; Formica V; Salani F; Winchler C; Bergamo F; Balsano R; Gusmaroli E; Lorenzo A; Landriscina M; Pretta A; Toma I; Pirrone C; Diana A; Leone F; Brunetti O; Brandi G; Garattini SK; Satolli MA; Rossari F; Fornaro L; Niger M; Zanuso V; De Rosa A; Ratti F; Aldrighetti L; De Braud F; Foti S; Rizzato MD; Vivaldi C; Stefano C; Rimassa L; Antonuzzo L; Casadei-Gardini A
Target Oncol; 2024 May; 19(3):359-370. PubMed ID: 38691295
[TBL] [Abstract][Full Text] [Related]
19. A randomized phase II study of weekly nab-paclitaxel plus gemcitabine or simplified LV5FU2 as first-line therapy in patients with metastatic pancreatic cancer: the AFUGEM GERCOR trial.
Bachet JB; Chibaudel B; Bonnetain F; Validire P; Hammel P; André T; Louvet C;
BMC Cancer; 2015 Oct; 15():653. PubMed ID: 26445094
[TBL] [Abstract][Full Text] [Related]
20. Capecitabine plus oxaliplatin versus gemcitabine plus oxaliplatin as first-line therapy for advanced biliary tract cancers: a multicenter, open-label, randomized, phase III, noninferiority trial.
Kim ST; Kang JH; Lee J; Lee HW; Oh SY; Jang JS; Lee MA; Sohn BS; Yoon SY; Choi HJ; Hong JH; Kim MJ; Kim S; Park YS; Park JO; Lim HY
Ann Oncol; 2019 May; 30(5):788-795. PubMed ID: 30785198
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
